Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
0.350
-0.002 (-0.54%)
Dec 27, 2024, 9:43 AM EST - Market open
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2023. The number of employees increased by 3 or 50.00% compared to the previous year.
Employees
9
Change (1Y)
3
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,723,969
Market Cap
1.50M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | 3 | 50.00% |
| Dec 31, 2022 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Scorpius Holdings | 84 |
| China SXT Pharmaceuticals | 75 |
| Molecular Templates | 62 |
| TC Biopharm (Holdings) | 41 |
| TransCode Therapeutics | 10 |
| Virpax Pharmaceuticals | 7 |
| Aclarion | 6 |
| SciSparc | 3 |
REVB News
- 24 days ago - Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds - Business Wire
- 25 days ago - Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND - Business Wire
- 6 weeks ago - Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply - Business Wire
- 6 weeks ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 - Business Wire
- 3 months ago - Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10 - Business Wire
- 4 months ago - Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds - Business Wire
- 4 months ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024 - Business Wire
- 6 months ago - Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity - Business Wire